Hepatology

Papers
(The H4-Index of Hepatology is 71. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Reply: Fiber and whole grain intakes in relation to liver cancer risk—An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies2667
Reply: Liver stiffness progression comparison between diabetics and non-diabetics with biopsy-proven metabolic dysfunction–associated steatosis2291
Honey, I shrunk the tumor: Downstaging HCC before liver transplantation2060
Stellate cell-specific adhesion molecule protocadherin 7 regulates sinusoidal contraction1503
Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis539
Letter to the Editor: Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury334
Reply: Medications promoting abstinence in alcohol-associated cirrhosis322
Late-Breaking Abstracts316
Post-vax vein vigilance: Unmasking splanchnic thrombosis risks281
Boosting Success: Optimizing Thiopurine Therapy in Autoimmune Hepatitis With Allopurinol242
Cover Image237
Letter to the editor: The precise relationship between MELD and survival without a liver transplant204
More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC200
Hepatic encephalopathy—We are no longer those who believe that reality is what we perceive199
Letter to the Editor: Real-world evidence supports nephrotoxic risk of anakinra plus zinc in alcohol-associated hepatitis186
Letter to the Editor: The Hepa 1–6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy173
Reply159
Reply: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?150
Letter to the Editor: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD145
Regulatory role and translational potential of CCL11 in liver fibrosis142
Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients142
Biopsy-free endpoints in MASH trials: A comparative look at MASHResInd and FAST133
Reply: Timing shapes adjuvant PD-1 efficacy after hepatectomy in HCC132
Retraction: GABA induces the differentiation of small into large cholangiocytes by activation of Ca2+/CaMK I-dependent adenylyl cyclase 8129
Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosis127
Reply: The PNPLA3 paradox—Does genotype modify the clinical utility of the MASLD framework in children?124
Multi-omics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma122
PGD2/DP1 axis promotes liver regeneration by secreting Wnt2 in KCs in mice122
Moving beyond the liver—Proteomics as a molecular footprint of systemic damage in metabolic dysfunction–associated steatotic liver disease118
Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals118
Low-dose chemotherapy remodels hepatic immune landscape and potentiates anti-tumor response to immune checkpoint blockade in cholangiocarcinoma117
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study115
Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis113
Access to technology to support telehealth in areas without specialty care for liver disease106
ZNT1 and Zn2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor106
Development and validation of risk stratification models for hepatocellular cancer: A framework from the translational liver cancer consortium105
Implementation of a controlled human infection model for evaluation of HCV vaccine candidates105
Letter to the Editor: LO2, a misidentified cell line: Some data should be interpreted with caution104
Efficacy and safety of infliximab in patients with autoimmune hepatitis101
Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis101
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease100
Plasma proteomic signature of fatty liver disease: The Rotterdam Study100
Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death99
Letter to the Editor: Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma98
98
Genes that fit just right: Unzipping the genome of fatty liver disease98
Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatm97
Letter to the Editor: Primary sclerosing cholangitis and autoimmune hepatitis—Distinct or common autoimmune penetrance?97
Letter to the Editor: Insights into immune-mediated adverse events and survival outcomes—Lessons from HIMALAYA96
Letter to the Editor: Screening and risk stratification disparities in Hispanic MASLD95
Reply: Is fecal acetate a viable pan-etiological predictor of outcomes in HCC immunotherapy?91
Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis90
Amplification of genetic and metabolic factors in alpha-1 antitrypsin deficiency88
Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries’ framework for digital twin advancement87
Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma85
Erratum: Vps4A functions as a tumor suppressor by regulating the secretion and uptake of exosomal microRNAs in human hepatoma cells85
Hepatocellular carcinomas, exhibiting intratumor fibrosis, express cancer-specific extracellular matrix remodeling and WNT/TGFB signatures, associated with poor outcome84
Reply: Several issues to consider in the study of hepatocellular carcinoma progression mechanism84
Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study79
Use of noninvasive scores to predict hepatic steatosis: Flaws and caveats79
Solving the puzzle of fibrosis resolution in alcohol-associated liver disease: An insight from KDM5 demethylases and LXR activation78
Understanding advanced cystic fibrosis liver disease through genetic variation: Where do the pathways lead and how much further must we go?77
Letter to the Editor: Overlooking the important factor: Hypoxia76
Erratum: Identification and characterization of a hepatic IL-13–producing ILC3-like population potentially involved in liver fibrosis76
Clinical decision support and electronic interventions to improve care quality in chronic liver diseases and cirrhosis75
5S rRNA pseudogene transcripts are associated with interferon production and inflammatory responses in alcohol-associated hepatitis75
Reply: How does bile acid–induced IRF3 phosphorylation mediate cholestatic liver and kidney injury?—More needs to be known75
Much more needed in natural history of Alagille syndrome74
The international quest for the imaging diagnosis of liver cancer74
Reply: Diabetes and fibrosis—Parallel risks or overlap?74
CD44 in myEloid cells is a major driver of liver inflammation and injury in alcohol-related liver disease72
0.78216505050659